Basel, August 28, 2023 – Sandoz, a global leader in generic and biosimilar medicines, has successfully completed the acquisition of worldwide brand rights for leading systemic antifungal agent Mycamine ® (micafungin sodium, Funguard® in Japan) from Astellas.
Enforcement Report - Week of February 22, 2023
Generics giant and Novartis division Sandoz signed a deal with Astellas for worldwide rights to the antifungal drug micafungin sodium, also known as Mycamine.
Zydus Lifesciences said Wednesday it has received the final nod from the US health regulator to market its generic Micafungin injection, which is used to treat a variety of fungal infections.
Zydus's Generic Micafungin Sodium Receives Approval in the U.S.
Nanjing's Generic Micafungin Sodium Receives Approval in the U.S.
Enforcement Report - Week of September 1, 2021
Xellia Pharms Aps's Generic Micafungin Sodium Receives ApprovalIn US
Astellas Pharma Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for MYCAMINE® (micafungin for injection) in support of the treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age.
Astellas Pharma Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for MYCAMINE® (micafungin for injection) in support of the treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age.